Blood-based biomarkers and major adverse cardiac events after percutaneous coronary intervention: a systematic review with narrative synthesis
Major adverse cardiac events (MACE) remain common after percutaneous coronary intervention (PCI) despite advances in stent technology and secondary-prevention pharmacotherapy. Blood-based biomarkers have been proposed as tools for individualised risk stratification, but reported prognostic associations vary widely...